Search results for " Gadobenate dimeglumine"

showing 2 items of 2 documents

Diagnostic performance of gadobenate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial

2007

OBJECTIVE. The purpose of this study was to compare gadobenate dimeglumine–enhanced MR angiography and unenhanced time-of-flight MR angiography for the detection of significant peripheral arterial occlusive disease using digital subtraction angiography as our reference standard. SUBJECTS AND METHODS. Two hundred seventy-two patients underwent MR angiography and digital subtraction angiography of the iliofemoral arteries. MR angiography was performed before (2D time-of-flight acquisitions) and after (spoiled gradient-echo acquisitions) the administration of 0.1 mmol/kg of gadobenate dimeglumine at 1–2 mL/s. Contrast-enhanced MR angiography and digital subtraction angiography of the calf arte…

AdultMalemedicine.medical_specialtyContrast MediaLumen (anatomy)Arterial Occlusive DiseasesArterial Occlusive Diseases/*diagnosis Contrast Media Image Enhancement/*methods Magnetic Resonance Angiography/*methods Meglumine/*analogs & derivatives/therapeutic useSensitivity and SpecificityMegluminecontrast agents; diagnostic performance; gadobenate dimeglumine; MR angiography; peripheral arterial occlusive diseasediagnostic performancePeripheral arterial occlusive diseaseMulticenter trialOrganometallic CompoundsHumansMedicineRadiology Nuclear Medicine and imagingcontrast agentsGADOBENATE DIMEGLUMINEAgedPeripheral Vascular DiseasesMR angiographymedicine.diagnostic_testbusiness.industryVascular diseaseMr angiographyReproducibility of ResultsGeneral MedicineDigital subtraction angiographyMiddle AgedSouth Americacontrast agentImage Enhancementmedicine.diseaseEuropemedicine.anatomical_structureThighFemaleRadiologybusinessperipheral arterial occlusive diseaseMagnetic Resonance AngiographyArterygadobenate dimeglumine
researchProduct

Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?

2020

Purpose: To compare the level of parenchymal and portal venous enhancement in the portal venous phase (PVP) in cirrhotic patients undergoing gadoxetate disodium- and gadobenate dimeglumine-enhanced MRI. Methods: In this retrospective study, 84 cirrhotic patients (mean age ± SD: 66 ± 13 years) who underwent contrast-enhanced MRI with both gadoxetate disodium and gadobenate dimeglumine between 2012 and 2018 were included. Two readers measured signal intensities of hepatic parenchyma, portal vein and psoas muscle on precontrast and PVP. Relative enhancement (RE), image contrast, and portal vein-to-liver contrast difference were calculated. Intraindividual differences were compared with the Wil…

Gadolinium DTPALiver Cirrhosismedicine.medical_specialtyCirrhosisUrologyPortal veinContrast MediaPortal venous phase030218 nuclear medicine & medical imagingGadoxetate Disodium03 medical and health sciences0302 clinical medicinePrecontrastMeglumineInternal medicineGadobenate dimegluminemedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingGADOBENATE DIMEGLUMINEAgedRetrospective StudiesCirrhosis Portal vein Gadobenate dimeglumine Gadoxetate disodium Hepatic parenchymaHepatic parenchymaRadiological and Ultrasound Technologybusiness.industryGastroenterologyHepatologyMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingCirrhosisHepatic parenchyma030220 oncology & carcinogenesisPortal veinGadoxetate disodiumNuclear medicinebusiness
researchProduct